12 September 2019 - The guidance relates to the use of pembrolizumab in combination with carboplatin and paclitaxel on the NHS by patients with untreated metastatic squamous non-small-cell lung cancer.

Pembrolizumab, with carboplatin and paclitaxel, is recommended for use within the Cancer Drugs Fund as an option for untreated metastatic squamous non-small-cell lung cancer in adults only if:

• pembrolizumab is stopped at 2 years of uninterrupted treatment, or earlier if disease progresses, and
• Merck provides pembrolizumab according to the managed access agreement.

Read NICE Technology Appraisal Guidance